NASDAQ:ORKA Oruka Therapeutics (ORKA) Stock Price, News & Analysis $60.61 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$60.87 +0.26 (+0.43%) As of 05/22/2026 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Oruka Therapeutics Stock (NASDAQ:ORKA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oruka Therapeutics alerts:Sign Up Key Stats Today's Range$57.98▼$61.1550-Day Range$31.99▼$76.3952-Week Range$10.64▼$91.00Volume1.10 million shsAverage Volume2.46 million shsMarket Capitalization$3.66 billionP/E RatioN/ADividend YieldN/APrice Target$120.80Consensus RatingModerate Buy Company Overview Oruka Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.” The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy. In addition to ONCT-01, Oruka’s pipeline includes multiple preclinical programs directed at key targets such as MDM2-p53 and MYC, reflecting a broad strategy to address unmet needs across various tumor types. The company’s research efforts extend to both monotherapy and combination therapy approaches to enhance anti‐tumor activity. Headquartered in the United States, Oruka Therapeutics became a publicly traded company in 2022 and is listed on the NASDAQ under the symbol ORKA. The organization is led by a management team with extensive experience in peptide chemistry, oncology drug development and clinical operations. Oruka continues to advance its technology platform and pipeline toward the goal of delivering innovative cancer treatments to patients worldwide.AI Generated. May Contain Errors. Read More Oruka Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreORKA MarketRank™: Oruka Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 190th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingOruka Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialOruka Therapeutics has a consensus price target of $120.80, representing about 99.3% upside from its current price of $60.61.Amount of Analyst CoverageOruka Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Oruka Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Oruka Therapeutics are expected to decrease in the coming year, from ($2.05) to ($2.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oruka Therapeutics is -31.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oruka Therapeutics is -31.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOruka Therapeutics has a P/B Ratio of 7.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oruka Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.21% of the float of Oruka Therapeutics has been sold short.Short Interest Ratio / Days to CoverOruka Therapeutics has a short interest ratio ("days to cover") of 2.62, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oruka Therapeutics has recently increased by 26.27%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOruka Therapeutics does not currently pay a dividend.Dividend GrowthOruka Therapeutics does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment0.61 News SentimentOruka Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Oruka Therapeutics this week, compared to 4 articles on an average week.Search Interest9 people have searched for ORKA on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat Follows3 people have added Oruka Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Oruka Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,095,785.00 in company stock.Percentage Held by Insiders23.49% of the stock of Oruka Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.44% of the stock of Oruka Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Oruka Therapeutics' insider trading history. Receive ORKA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oruka Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORKA Stock News HeadlinesCarl Dambkowski Sells 105,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) StockMay 24 at 4:11 AM | americanbankingnews.comOruka Therapeutics (NASDAQ:ORKA) Director Carl Dambkowski Sells 105,000 SharesMay 23 at 7:50 AM | insidertrades.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 25 at 1:00 AM | Profits Run (Ad)Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 10,290 SharesMay 19, 2026 | americanbankingnews.comOruka Therapeutics (NASDAQ:ORKA) SVP Sells $607,830.30 in StockMay 19, 2026 | insidertrades.comInsider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $432,950.00 in StockMay 18, 2026 | americanbankingnews.comOruka Therapeutics (ORKA) Valuation Check After Psoriasis Trial Progress Partnerships And Fresh FundingMay 16, 2026 | finance.yahoo.comOruka Therapeutics (NASDAQ:ORKA) Insider Sells $432,950.00 in StockMay 16, 2026 | insidertrades.comSee More Headlines ORKA Stock Analysis - Frequently Asked Questions How have ORKA shares performed this year? Oruka Therapeutics' stock was trading at $30.31 at the beginning of 2026. Since then, ORKA shares have increased by 100.0% and is now trading at $60.61. How were Oruka Therapeutics' earnings last quarter? Oruka Therapeutics, Inc. (NASDAQ:ORKA) announced its earnings results on Wednesday, May, 13th. The company reported ($0.48) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.04. Who are Oruka Therapeutics' major shareholders? Top institutional investors of Oruka Therapeutics include Remedium Capital Partners LLC (2.60%), Affinity Asset Advisors LLC (1.00%), Candriam S.C.A. (0.82%) and Atika Capital Management LLC (0.46%). Insiders that own company stock include Venrock Healthcare Capital Par, Lawrence Otto Klein, Joana Goncalves and Arjun Agarwal. View institutional ownership trends. How do I buy shares of Oruka Therapeutics? Shares of ORKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oruka Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oruka Therapeutics investors own include Astria Therapeutics (ATXS), Aldeyra Therapeutics (ALDX), Black Diamond Therapeutics (BDTX), Energy Transfer (ET), Heron Therapeutics (HRTX), Skye Bioscience (SKYE) and NuScale Power (SMR). Company Calendar Last Earnings5/13/2026Today5/25/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ORKA's financial health is in the Green zone, according to TradeSmith. ORKA has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORKA Previous SymbolNASDAQ:ORKA CIK907654 Webwww.arcabio.com Phone720-940-2100Fax720-208-9261EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Oruka Therapeutics$120.80 High Price Target$200.00 Low Price Target$45.00 Potential Upside/Downside+99.3%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($1.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$105.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-26.16% Return on Assets-25.00% Debt Debt-to-Equity RatioN/A Current Ratio23.76 Quick Ratio23.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.02 per share Price / Book7.56Miscellaneous Outstanding Shares60,310,000Free Float46,145,000Market Cap$3.66 billion OptionableN/A Beta-0.20 The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:ORKA) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
